GQG.ASX VYS.ASX BOT.ASX AVH.ASX KAL.ASX

Smooth and Engaging News Roundup

GQG Partners Delivers Solid 2025 Results

GQG Partners Inc. had a strong year in 2025, reporting impressive growth across key financial metrics. The asset manager's funds under management (FUM) reached a record $163.9 billion, up 7.1% from 2024, driven by solid investment performance. This translated to a 6.3% increase in net revenue to $808.3 million and a 7.3% rise in net income to $463.3 million.

The company's diverse range of strategies, including Global Equity, Emerging Markets Equity, US Equity, and International Equity, all outperformed their respective benchmarks over various time periods. GQG's focus on protecting client capital and investing in high-quality companies has served it well through different market cycles.

Looking ahead, GQG remains well-positioned to navigate the evolving investment landscape, with a talented and aligned team, robust risk management practices, and a commitment to adaptability. The board has also declared a fourth-quarter dividend of $0.0365 per share, maintaining the company's strong payout ratio.

Vysarn Advances Kariyarra Water Scheme

Elsewhere, Vysarn Ltd announced progress on its joint venture with the Kariyarra Aboriginal Corporation to develop water resources in the Pilbara region of Western Australia. The Kariyarra Aboriginal Corporation has formally submitted a detailed hydrogeological assessment for the Kariyarra Water Scheme, a crucial step in securing the necessary groundwater licenses.

Vysarn's wholly owned subsidiary, Pentium Water, prepared the comprehensive H3 Report, which supports the Kariyarra's application for a groundwater license of up to 10 GL per annum over 30 years. This joint venture aims to investigate, assess, manage, and supply water from identified resources on Kariyarra country, with Vysarn actively pursuing commercial discussions with potential off-takers.

Botanix Pauses Trading, Potential Capital Raise

In other news, Botanix Pharmaceuticals Ltd has requested a trading halt of its securities, pending an announcement regarding a potential capital raising. The trading halt will remain in place until the earlier of the announcement's release or the market open on 17 February 2026. The company stated that it is not aware of any reason why the trading halt should not be granted.

AVITA Stabilizes Business, Positions for Growth

AVITA Medical reported its fourth-quarter and full-year 2025 financial results, showcasing the company's progress in stabilizing its revenue performance and positioning itself for growth in 2026. While Q4 revenue declined 4% year-over-year due to reimbursement headwinds, full-year revenue increased 11% to $71.6 million.

AVITA has enhanced its commercial model, gained reimbursement clarity, and advanced its post-market clinical programs for Cohealyx and PermeaDerm. The company has also secured a $60 million credit facility to strengthen its capital structure and support long-term growth. Looking ahead, AVITA expects to deliver revenue growth of 12% to 19% in 2026, reaching $80 to $85 million.

KalGold Uncovers Deeper Gold Mineralization

Kalgoorlie Gold Mining Ltd (KalGold) reported exciting results from its first diamond drilling program at the Kirgella Gift and Providence deposits within the Pinjin Project. The drilling confirmed that primary gold mineralization extends to a depth of 300 meters, significantly deeper than previous drilling. KalGold has identified new targets for follow-up to test the vertical continuity and potential repetition of the high-grade mineralization.

These results provide valuable insights to support future resource upgrades and demonstrate the potential for further discoveries within the broader Pinjin Project area. KalGold plans to conduct additional drilling programs to continue defining the extent of gold mineralization.